The immunosuppressive potential of misoprostol - Efficacy and variability

Clinical Immunology

Volumn 109, Issue 3, 2003, Pages 288-294

  Waiser, Johannes ^a   Böhler, Torsten ^a   Stoll, Juliane ^a   Schumann, Brit ^a   Budde, Klemens ^a   Neumayer, Hans Hellmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cytokines; IFN ; IL 10; IL 2; IL 4; Lymphocyte proliferation; Misoprostol; Phagocytosis; Th1 Th2

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MISOPROSTOL;

ADULT; ARTICLE; BIOAVAILABILITY; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MALE; PRIORITY JOURNAL; REDUCTION; TH1 CELL;

EID: 0346494391     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2003.08.009     Document Type: Article

References (48)

1. Phipps R.P., Stein S.H., Roper R.L. A new view of prostaglandin E regulation of the immune response. Immunol. Today. 12:1991;349-352.
2. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today. 9:1988;222-229.
3. 2. J. Immunol. 145:1990;2616-2625.
4. Krause D.S., Deutsch C. Cyclic AMP directly inhibits IL-2 receptor expression in human T cells Expression of both p55 and p75 subunits is affected . J. Immunol. 146:1991;2285-2294.
5. Wacholtz M.C., Minakuchi R., Lipsky P.E. Characterization of the 3′,5′ cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cell. Immunol. 135:1991;285-298.
6. 2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur. J. Immunol. 18:1988;1791-1796.
7. Johnson K.W., Smith K.A. cAMP regulation of IL-2 receptor expression selective modulation of the p75 subunit . J. Immunol. 145:1990;1144-1151.
8. Munoz E., Zubiaga A.M., Merrow M., Sauter N.P., Huber B.T. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation role of cAMP in T cell proliferation . J. Exp. Med. 172:1990;95-103.
9. Novak T., Rothenberg E. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. USA. 87:1990;9353-9357.
10. H2 lymphokines. J. Immunol. 146:1991;108-113.
11. + T cells inhibits acquisition of ability to produce IFN-γ and IL-2, but not IL-4 and IL-5. J. Immunol. 155:1995;4604-4612.
12. Dooper M.M.B.W., Wassink L., M'Rabet L., Graus Y.M.F. The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype. Immunology. 107:2002;152-159.
13. 2 suppression of in vitro lymphoid responses to alloantigen. Transplant. Proc. 21:1989;3769-3770.
14. Neumayer H.H., Schreiber M., Wagner K. Prevention of delayed graft function by Diltiazem and Iloprost. Transplant. Proc. 21:1989;1221-1224.
15. Moncada S., Vane J.R. Short term suppression of hyperacute renal allograft rejection in presensitised dogs with prostacyclin. Prostaglandins. 19:1980;595-603.
16. Strom T.B., Carpenter C.B. Prostaglandin as an effective antirejection therapy in rat renal allograft recipients. Transplantation. 35:1983;279-281.
17. Moran M., Mozes M.F., Maddux M.S., Veremis S., Bartkus C., Ketel B., Pollak R., Wallemark C., Jonasson O. Prevention of acute graft rejection by the prostaglandine E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N. Engl. J. Med. 322:1990;1183-1188.
18. Rowles J.R., Foegh M.L., Khirabadi B.S., Ramwell P.W. The synergistic effect of cyclosporine and iloprost on survival of rat cardiac allografts. Transplantation. 42:1986;94-96.
19. Wiederkehr J.C., Dumble L., Pollak R., Moran M. Immunosuppressive effect of misoprostol a new synthetic prostaglandin E1 analogue . Aust. NZ J. Surg. 60:1990;121-124.
20. Olsen T.W., Gothard T.W., Holland E.J. Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model. Cornea. 15:1996;76-81.
21. Pouteil-Noble C., Chapuis F., Berra N., Hadj-Aissa A., Lacavalerie B., Lefrancois N., Martin X., Touraine J.L. Misoprostol in renal transplant recipients a prospective, randomized, controlled study on the prevention of acute rejection episodes and cyclosporine A nephrotoxicity . Nephrol. Dial. Transplant. 9:1994;552-555.
22. Curtis L.D., Anwar N., Briggs J.D., Buckels J.A.C., Jones M., Karim M.S., Koffman G., McGregor E., Neild G., Riad H.N. Misoprostol in renal transplantation. Transplant. Proc. 25:1993;602.
23. Cofer B.R., Davies C.B., Alexander J.W., Tchervenkov J.I. The effect of the prostaglandin analogues misoprostil and enisoprost on the synergy between donor-specific transfusion and cyclosporine in allograft survival. Transplantation. 54:1992;941-943.
24. Wilkie M.E., Beer J.C., Newman D., Raftery M.J., Marsh F.P. Evidence that the risks of misoprostol outweigh its benefits in stable cyclosporine-treated renal allograft recipients. Transplantation. 54:1992;565-567.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays . J. Immunol. Methods. 65:1983;55-63.
26. Oliveira G., Xavier P., Murphy B., Neto S., Mendes A., Sayegh M., Guerra L.E. Cytokine analysis of human renal allograft aspiration biopsy cultures supernatants predicts acute rejection. Nephrol. Dial. Transplant. 13:1998;417-422.
27. Sayegh M.H., Akalin E., Hancock W.W., Russell M.E., Carpenter C.B., Linsley P.S., Turka L.A. CD28-B7 blockade after allogenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1995;1869-1874.
28. Reutzel-Selke A., Tullius S.G., Graser E., Nieminen-Kelhä M., Jonas S., Bechstein W.O., Neuhaus P., Volk H.-D. Mechanisms of tolerance induction in second renal allografts of a chronic rejection model. Transplant. Int. 13: (Suppl 1):2000;S476-S479.
29. Lehmann M., Graser E., Risch K., Hancock W.W., Muller A., Kuttler B., Hahn H.J., Kupiec-Weglinski J.W., Brock J., Volk H.D. Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells. Transplantation. 64:1997;1181-1187.
30. Tarumi K., Murakami M., Yagihashi A., Nakagawa I., Hirarata K., Uede T. CTLA4Ig treatment induces long-term acceptance of rat small bowel allografts. Transplantation. 67:1999;520-525.
31. Steiger J.U. Transplantation immunology is the manipulation of the cytokine network therapeutically justified . Schweiz. Med. Wochenschr. 128:1998;349-355.
32. Krams S.M., Falco D.A., Villanueva J.C., Rabkin J., Tomlanovich S.J., Vincenti F., Amend W.J., Melzer J., Garovoy M.R., Roberts J.P. Cytokine and T cell receptor gene expression at the site of allograft rejection. Transplantation. 53:1992;151-156.
33. Hancock W.W., Shi C., Picard M.H., Bianchi C., Russell M.E. LEW-to-F344 carotid artery allografts analysis of a rat model of posttransplant vascular injury involving cell-mediated and humoral responses . Transplantation. 60:1995;1565-1572.
34. Strom T.B., Roy-Chaudhury P., Manfro R., Zheng X.X., Nickerson P.W., Wood K., Bushell A. The Th1/Th2 paradigm and the allograft response. Curr. Opin. Immunol. 8:1996;688-693.
35. Kunzendorf U., Tran H., Bulfone-Paus S. The Th1/Th2 paradigm in 1998 law of nature or rule with exceptions . Nephrol. Dial. Transplant. 13:1998;2445-2448.
36. Pelletier M., Adolphe M., Fontagne J., Timsit J., Lechat P., Truhaut M.R. The effect of prostaglandins E1 and A2 on the proliferation and phagocytosis of mouse peritoneal macrophages in culture. C.R. Acad. Sci. Hebd. Seances Acad. Sci. D. 280:1975;1317-1320.
37. Mikawa K., Akamatsu H., Maekawa N., Nishina K., Obara H., Niwa Y. Inhibitory effect of prostaglandin E1 on human neutrophil function. Prostaglandins Leukot. Essent. Fatty Acids. 51:1994;287-291.
38. Davidson J., Kerr A., Guy K., Rotondo D. Prostaglandin and fatty acid modulation of Escherichia coli 0157 phagocytosis by human monocytic cells. Immunology. 94:1998;228-234.
39. Hutchison D.L., Myers R.L. Prostaglandin-mediated suppression of macrophage phagocytosis of Listeria monocytogenes. Cell. Immunol. 110:1987;68-76.
40. Rossi A.G., McCutcheon J.C., Roy N., Chilvers E.R., Haslett C., Dransfield I. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. J. Immunol. 160:1998;3562-3568.
41. Konopski Z., Seljelid R., Eskeland T. Cytokines and PGE2 modulate the phagocytic function of the beta-glucan receptor in macrophages. Scand. J. Immunol. 37:1993;587-592.
42. Sunder-Plassmann R., Majdic O., Knapp W., Holter W. In vitro and in vivo activated T cells display increased sensitivity to PGE2. Cell. Immunol. 138:1991;289-299.
43. Wilder R.L. Neuroendocrine-immune system interactions and autoimmunity. Annu. Rev. Immunol. 13:1995;307-338.
44. Da Silva J.A. Sex hormones and glucocorticoids interactions with the immune system . Ann. NY Acad. Sci. 876:1999;102-117.
45. Du J.T., Vennos E., Ramey E., Ramwell P.W. Sex differences in arachidonate cyclo-oxygenase products in elicited rat peritoneal macrophages. Biochim. Biophys. Acta. 794:1984;256-260.
46. Leslie C.A., Gonnerman W.A., Cathcart E.S. Gender differences in eicosanoid production from macrophages of arthritis-susceptible mice. J. Immunol. 138:1987;413-416.
47. Leslie C.A., Dubey D.P. Increased PGE2 from human monocytes isolated in the lutea phase of the menstrual cycle. Implications for immunity. Prostaglandins. 47:1994;41-54.
48. Pollak R., Dumble L.J., Wiederkehr J.C., Maddux M.S., Moran M. The immunosuppressive properties of new oral prostaglandin E1 analogs. Transplantation. 50:1990;834-838.